Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,178 | 33 | 98.7% |
| Education | $15.27 | 1 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $278.65 | 7 | $0 (2024) |
| UCB, Inc. | $195.41 | 2 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $189.21 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $98.46 | 3 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $69.82 | 1 | $0 (2018) |
| Lilly USA, LLC | $65.41 | 3 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $59.01 | 3 | $0 (2020) |
| Incyte Corporation | $47.19 | 2 | $0 (2024) |
| PFIZER INC. | $40.26 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $36.09 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $530.75 | 15 | UCB, Inc. ($195.41) |
| 2023 | $140.26 | 2 | ABBVIE INC. ($124.99) |
| 2021 | $42.90 | 2 | AbbVie Inc. ($26.16) |
| 2020 | $78.72 | 4 | AbbVie Inc. ($22.32) |
| 2019 | $74.40 | 4 | Sun Pharmaceutical Industries Inc. ($23.48) |
| 2018 | $167.03 | 4 | Janssen Scientific Affairs, LLC ($69.82) |
| 2017 | $158.93 | 3 | Regeneron Healthcare Solutions, Inc. ($134.74) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 2 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/06/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/15/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Immunology | ||||||
| 10/09/2018 | Sun Pharmaceutical Industries Inc. | ILUMYA (tildrakizumab-asmn) injection (Biological) | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: Dermatology | ||||||
| 03/06/2018 | Janssen Biotech, Inc. | Tremfya (Drug) | Food and Beverage | In-kind items and services | $26.15 | General |
| Category: Immunology | ||||||
| 01/31/2018 | Janssen Scientific Affairs, LLC | Tremfya (Drug) | Food and Beverage | In-kind items and services | $69.82 | General |
| Category: Immunology | ||||||
| 01/29/2018 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $50.48 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Immunology | ||||||
| 11/09/2017 | Regeneron Healthcare Solutions, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $122.04 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/12/2017 | Regeneron Healthcare Solutions, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,596 | 4,454 | $573,990 | $168,076 |
| 2022 | 15 | 1,598 | 5,012 | $560,889 | $160,569 |
| 2021 | 12 | 1,474 | 2,995 | $467,359 | $142,564 |
| 2020 | 11 | 1,233 | 2,216 | $354,415 | $94,761 |
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 20 | $9,500 | $2,792 | 29.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 25 | 35 | $7,980 | $1,890 | 23.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 18 | 18 | $6,372 | $1,859 | 29.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 11 | 11 | $2,717 | $635.25 | 23.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 357 | 472 | $109,976 | $34,545 | 31.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 197 | 249 | $85,407 | $26,737 | 31.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 259 | 351 | $79,686 | $18,382 | 23.1% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 144 | 166 | $57,892 | $16,710 | 28.9% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 50 | 65 | $31,980 | $10,611 | 33.2% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 200 | 1,379 | $26,201 | $9,583 | 36.6% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 62 | 82 | $19,024 | $9,521 | 50.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 122 | 138 | $19,872 | $6,553 | 33.0% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 24 | 27 | $11,502 | $3,594 | 31.2% |
| 17262 | Destruction of malignant growth (1.1 to 2.0 centimeters) of trunk, arms, or legs | Office | 2021 | 17 | 19 | $13,191 | $3,293 | 25.0% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 25 | 30 | $6,780 | $1,690 | 24.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 17 | 17 | $5,848 | $1,345 | 23.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 338 | 425 | $95,625 | $24,400 | 25.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 134 | 174 | $57,246 | $16,135 | 28.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 136 | 155 | $54,009 | $13,642 | 25.3% |
| 17000 | Destruction of skin growth | Office | 2020 | 213 | 270 | $59,881 | $12,707 | 21.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 57 | 63 | $13,813 | $6,786 | 49.1% |
| 17004 | Destruction of 15 or more skin growths | Office | 2020 | 30 | 38 | $17,822 | $5,611 | 31.5% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 156 | 892 | $16,056 | $5,347 | 33.3% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 95 | 111 | $15,207 | $4,056 | 26.7% |
| 11104 | Punch biopsy of single skin lesion | Office | 2020 | 24 | 24 | $10,224 | $2,735 | 26.7% |
About Dr. Renata Mullen, MD
Dr. Renata Mullen, MD is a Dermatology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760493068.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Renata Mullen, MD has received a total of $1,193 in payments from pharmaceutical and medical device companies, with $530.75 received in 2024. These payments were reported across 34 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($1,178).
As a Medicare-enrolled provider, Mullen has provided services to 5,901 Medicare beneficiaries, totaling 14,677 services with total Medicare billing of $565,970. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Palo Alto, CA
- Active Since 08/11/2006
- Last Updated 03/03/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1760493068
Products in Payments
- Bimzelx (Biological) $195.41
- RINVOQ (Biological) $156.14
- DUPIXENT DUPILUMAB INJECTION (Biological) $134.74
- Tremfya (Drug) $95.97
- SKYRIZI (Biological) $79.80
- COSENTYX (Biological) $70.90
- TALTZ (Drug) $65.41
- DUPIXENT (Biological) $54.47
- OPZELURA (Drug) $47.19
- Humira (Biological) $42.71
- ILUMYA (Biological) $38.43
- Sotyktu (Drug) $36.09
- XTRAC (Device) $29.28
- COSENTYX (Drug) $27.56
- EUCRISA (Drug) $24.99
- ILUMYA (tildrakizumab-asmn) injection (Biological) $20.58
- Seysara (Drug) $16.74
- CIBINQO (Drug) $15.27
- ADBRY (Biological) $13.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Palo Alto
John Doux, M.d, M.D
Dermatology — Payments: $124,944
Joyce Teng, Md, MD
Dermatology — Payments: $115,109
Shireen Guide, Md, MD
Dermatology — Payments: $79,371
Ilka Netravali, Md, MD
Dermatology — Payments: $28,025
Dr. Daniel Navi, M.d, M.D
Dermatology — Payments: $19,065
Dr. Thomas Hoffman, M.d, M.D
Dermatology — Payments: $17,860